Lymphir, Citius first FDA-approved product, is a reformulation of the FDA-approved cancer treatment denileukin diftitox, which combines the IL-2 cytokine and the diphtheria toxin
In real-world trials, fewer than 10% of patients discontinued both oral and injectable semaglutide due to side effects
25 These results are not considered to be clinically relevant and are not expected to impact the efficacy or safety of these agents
Its wise to request quotes from multiple licensed compounding pharmacies to find the best rate without compromising on quality
Disclaimer: This product is a dietary supplement and is not intended to diagnose, treat, cure, or prevent any disease
Get your personalized 30-day supply delivered directly to your home every month with a recurring subscription